Black Rock Inc. Adaptimmune Therapeutics PLC Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Black Rock Inc. holds 289,688 shares of ADAP stock, worth $327,347. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,688

Previous 179,581 61.31%

Holding current value

$327,347

Previous $141,000 224.11%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.7 - $1.75 $77,074 - $192,687	110,107 Added 61.31%	289,688 $457,000
Q4 2023 Feb 13, 2024	SELL	$0.43 - $0.79 $467,213 - $858,368	-1,086,543 Reduced 85.82%	179,581 $141,000
Q3 2023 Nov 13, 2023	BUY	$0.73 - $1.04 $75,917 - $108,155	103,996 Added 8.95%	1,266,124 $987,000
Q2 2023 Aug 11, 2023	BUY	$0.9 - $1.51 $250,344 - $420,023	278,161 Added 31.47%	1,162,128 $1.07 Million
Q1 2023 May 12, 2023	SELL	$1.06 - $2.16 $94,363 - $192,287	-89,022 Reduced 9.15%	883,967 $963,000

Q4 2022 Feb 13, 2023	SELL	$1.05 - $2.53 $463,320 - $1.12 Million	-441,258 Reduced 31.2%	972,989 $1.42 Million
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $50,180 - $114,089	47,340 Added 3.46%	1,414,247 $1.52 Million
Q2 2022 Aug 12, 2022	BUY	$1.33 - $2.28 $47,970 - $82,235	36,068 Added 2.71%	1,366,907 $2.32 Million
Q1 2022 May 12, 2022	BUY	$1.73 - $4.06 $277,052 - $650,192	160,146 Added 13.68%	1,330,839 $2.74 Million
Q4 2021 Feb 10, 2022	SELL	$3.5 - $5.68 $315,626 - $512,216	-90,179 Reduced 7.15%	1,170,693 $4.39 Million
Q3 2021 Nov 09, 2021	BUY	$3.44 - $6.37 $961,404 - $1.78 Million	279,478 Added 28.48%	1,260,872 $6.52 Million
Q2 2021 Aug 11, 2021	BUY	$3.86 - $5.78 $3.79 Million - $5.67 Million	981,394 New	981,394 $4.18 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

160M

Call Options Held

42.8K

Put Options Held

42.1K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $185M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account